Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PPIs For Infants: FDA Summons Advisory Panel, But Industry Unenthusiastic

This article was originally published in The Pink Sheet Daily

Executive Summary

In this instance, FDA seems more interested than the sponsors in a potential market expansion.

You may also be interested in...



Infant GERD Studies For PPIs Need Narrower Populations, Advisory Committee Says

FDA's Gastrointestinal Drugs Advisory Committee reaches broad agreement that the pathophysiology of GERD is not the same in infants as it is in adults, although a few are vocal that it is in fact the same.

Infant GERD Studies For PPIs Need Narrower Populations, Advisory Committee Says

FDA's Gastrointestinal Drugs Advisory Committee reaches broad agreement that the pathophysiology of GERD is not the same in infants as it is in adults, although a few are vocal that it is in fact the same.

Takeda Continues Post-patent Prevacid Hit, Looks Externally For Innovation And Leadership

TOKYO - Takeda, like most Japanese pharma, is hoping to counter the ongoing trend of patent expirations and yen appreciation by looking outward. Pushing beyond their comfort zones of Japan and U.S. markets, Japan's top pharma are pushing to gain ground in Europe and Asia. Similarly, these companies are looking outside of their own staff for expertise in these new regions

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS071516

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel